Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(Reuters) -Moderna on Thursday said it expected 2023 revenue of at least $6 billion, tempering its forecast to reflect weaker demand for COVID-19 vaccines, but added it would return to sales growth in 2025 and break even the following year. The company reported third-quarter sales of $1.8 billion, topping analysts' estimates of $1.32 billion, according to LSEG data. Moderna's COVID-19 vaccine is its lone marketed product.
By Maggie Fick and Bhanvi Satija (Reuters) - Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to exten...
Belgium’s drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisk's popular obesity drug Wegovy, in which the injector pens contained insulin.
Belgium’s drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisk's popular obesity drug Wegovy, in which the injector pens contained insulin. ...
Belgium’s drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisk's popular obesity drug Wegovy, in which the injector pens contained insulin. The Federal Agency for Medicines and Health Products told Reuters that this year it had detained nine mailed packages of GLP-1 medicines, the class of drugs that includes Wegovy and Novo's diabetes drug Ozempic, on the suspicion that they were fake.